LAFO RESIDENTATO 20 MAR 2006

SEQUENCE LISTING

<110>	Bayer HealthCare AG Golz, Stefan Brüggemeier, Ulf Geerts, Andreas	
<120>	Diagnostics and Therapeutics for Diseases Associat G-Protein Coupled Receptor ADIPOR1 (ADIPOR1)	ed with
<130>	LeA 36 901	
<150> <151>		
<150> <151>		
<160>	5	
<170>	PatentIn version 3.3	
<210> <211> <212> <213>		·
<400> ggcgctg	1 tgaag atcggggccg ctcggccgca ggccgcctcc agcgccgcgg ga	itatagogo 60
	accgc ggcccccagc agagcccgcc tgcccggctt gtctaccatc ag	
	cccc tggggctgag agaccccaac ctttccccaa gctgaagctg ca	
	ccagc cagatgtctt cccacaaagg atctgtggtg gcacagggga at	
	gtaac agggaagctg acacggtgga actggctgaa ctgggacccc tg	
	gcaaa cgggtaatcg ccaacccacc caaagctgaa gaagagcaaa ca	
	aggaa gaagaggagg aggtgcgggt actgacactt cccctgcaag cc	
catggag	agaag atggaagagt ttgtgtacaa ggtctgggag ggacgttgga gg	gtcatccc 480
atatgat	atgtg ctccctgact ggctaaagga caacgactat ctgctacatg gt	catagacc 540
tcccatg	tgccc tcctttcggg cttgcttcaa gagcatcttc cgcattcata ca	gaaactgg 600
caacato	tctgg acccatctgc ttggtttcgt gctgtttctc tttttgggaa tc	ttgaccat 660
gctcaga	gacca aatatgtact tcatggcccc tctacaggag aaggtggttt tt	gggatgtt 720
ctttttg	gggt gcagtgctct gcctcagctt ctcctggctc tttcacaccg tc	tattgtca 780
ttcagag	agaaa gtctctcgga ctttttccaa actggactat tcagggattg ct	cttctaat 840
tatgggg	gagc tttgtcccct ggctctatta ttccttctac tgctccccac ag	ccacggct 900
catctac	cctc tccatcgtct gtgtcctggg catttctgcc atcattgtgg cg	cagtggga 960
ccggttt	tgcc actcctaagc accggcagac aagagcaggc gtgttcctgg ga	cttggctt 1020
gagtggc	cgtc gtgcccacca tgcactttac tatcgctgag ggctttgtca ag	gccaccac 1080
agtgggc	ccag atgggctggt tcttcctcat ggctgtgatg tacatcactg ga	gctggcct 1140
ttatgct	tgct cgaattcctg agcgcttctt tcctggaaaa tttgacatat gg	ttccagtc 1200
tcatcag	gatt ttccatgtcc tggtggtggc agcagccttt gtccacttct at Page 1	ggagtctc 1260

```
Caaccttcag gaattccgtt acggcctaga aggcggctgt actgatgaca cccttctctg
                                                                1320
agccttccca cctgcggggt ggaggaggaa cttcccaagt gcttttaaaa ataacttctt
                                                                1380
tgctgaagtg agaggaagag tctgagttgt ctgtttctag aagaaacctc ttagagaatt
                                                                1440
cagtaccaac caagcttcag cccactttca cacccactgg gcaataaact ttccatttcc
                                                                1500
attctcctag ctggggatgg ggcatggtca aacttagcca tcccctcctc agcaaggcat
                                                                1560
ctaccggccc ctcacagaga cagtactttg aaactcatgt tgagatttta ccctctcctc
                                                                1620
                                                                1680
caaccatttt gggaaaatta tggactggga ctcttcagaa attctgtctt ttcttctgga
agaaaatgtc cctcccttac ccccatcctt aactttgtat cctggcttat aacaggccat
                                                                1740
ccatttttgt agcacacttt tcaaaaacaa ttatataccc tggtcccatc tttctagggc
                                                                1800
ctggatctgc ttatagagca ggaagaataa agccaccaac ttttacctag cccggctaat
                                                                1860
catggaagtg tgtccaggct tcaagtaact tgagttttaa ttttttttt ttcttggcaq
                                                                1920
                                                                1980
agtaatgtaa aatttaaatg gggaaagata tttaatattt aatactaagc tttaaaaaga
aacctgctat cattgctatg tatcttgatg caaagactat gatgttaata aaagaaagta
                                                                2040
2100
```

```
<210> 2
<211> 375
<212> PRT
```

<213> Homo sapiens

<400> 2

Met Ser Ser His Lys Gly Ser Val Val Ala Gln Gly Asn Gly Ala Pro 1 10 15

Ala Ser Asn Arg Glu Ala Asp Thr Val Glu Leu Ala Glu Leu Gly Pro 20 25 30

Leu Leu Glu Glu Lys Gly Lys Arg Val Ile Ala Asn Pro Pro Lys Ala 35 40 45

Glu Glu Glu Gln Thr Cys Pro Val Pro Gln Glu Glu Glu Glu Val 50 55 60

Arg Val Leu Thr Leu Pro Leu Gln Ala His His Ala Met Glu Lys Met 65 70 75 80

Glu Glu Phe Val Tyr Lys Val Trp Glu Gly Arg Trp Arg Val Ile Pro 85 90 95

Tyr Asp Val Leu Pro Asp Trp Leu Lys Asp Asn Asp Tyr Leu Leu His 100 105 110

Gly His Arg Pro Pro Met Pro Ser Phe Arg Ala Cys Phe Lys Ser Ile 115 120 125

Phe Arg Ile His Thr Glu Thr Gly Asn Ile Trp Thr His Leu Leu Gly 130 140 Phe Val Leu Phe Leu Phe Leu Gly Ile Leu Thr Met Leu Arg Pro Asn 150 155 160 Met Tyr Phe Met Ala Pro Leu Gln Glu Lys Val Val Phe Gly Met Phe 165 170 175 Phe Leu Gly Ala Val Leu Cys Leu Ser Phe Ser Trp Leu Phe His Thr 180 185 190 Val Tyr Cys His Ser Glu Lys Val Ser Arg Thr Phe Ser Lys Leu Asp 195 200 205 Tyr Ser Gly Ile Ala Leu Leu Ile Met Gly Ser Phe Val Pro Trp Leu 210 220 Tyr Tyr Ser Phe Tyr Cys Ser Pro Gln Pro Arg Leu Ile Tyr Leu Ser 225 230 235 240 Ile Val Cys Val Leu Gly Ile Ser Ala Ile Ile Val Ala Gln Trp Asp 245 250 255 Arg Phe Ala Thr Pro Lys His Arg Gln Thr Arg Ala Gly Val Phe Leu 260 265 270 Gly Leu Gly Leu Ser Gly Val Val Pro Thr Met His Phe Thr Ile Ala 275 280 285 Glu Gly Phe Val Lys Ala Thr Thr Val Gly Gln Met Gly Trp Phe Phe 290 295 300 Leu Met Ala Val Met Tyr Ile Thr Gly Ala Gly Leu Tyr Ala Ala Arg 305 310 315 320 Ile Pro Glu Arg Phe Phe Pro Gly Lys Phe Asp Ile Trp Phe Gln Ser 325 330 335 His Gln Ile Phe His Val Leu Val Val Ala Ala Ala Phe Val His Phe 340 345 350 Tyr Gly Val Ser Asn Leu Gln Glu Phe Arg Tyr Gly Leu Glu Gly Gly 355 360 365 Cys Thr Asp Asp Thr Leu Leu 370 375

<210> <211> 19 DNA

Artificial

<220> <223>	Primer1 (forward primer)	
	3 ggca aacgggtaa	19
	4 19 DNA Artificial	
<220> <223>	Primer2 (reverse primer)	
<400> ctcttc	4 ttcc tggggcact	19
	5 24 DNA Artificial	
<220> <223>	Probe1	
<400> cccacce	5 caaa gctgaagaag agca	24